Platelet directional-release growth factor composition and preparation method thereof

A growth factor and composition technology, which is applied in the field of platelet-directed release of growth factor composition and its preparation, can solve the problems of unstable therapeutic effect of autologous platelet-rich plasma, and improve therapeutic effect and efficiency, increase efficiency, inhibit Effects on Growth and Metastasis

Inactive Publication Date: 2019-07-26
NANJING FIRST HOSPITAL
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These growth factors have different effects on wound healing, so the therapeutic effect of autologous platelet-rich plasma in the field of cartilage tissue repair is not stable, and there is no method in the prior art that can effectively improve the effect of autologous platelet-rich plasma in various medical Field of Treatment Efficiency

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Platelet directional-release growth factor composition and preparation method thereof
  • Platelet directional-release growth factor composition and preparation method thereof
  • Platelet directional-release growth factor composition and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Embodiment 1: A kind of composition and its preparation method for targeted release of growth factors from platelets

[0028] The composition of platelet directional release growth factor comprises: 1 μl PAR, 100mlPRP (autologous platelet-rich plasma, wherein the platelet content is 1×10 7 ), 1 μl heparin.

[0029] Its preparation method is as follows:

[0030] S1. Add PAR thrombin receptor and heparin to autologous platelet-rich plasma, and manually stir and mix to obtain a mixed solution;

[0031] S2. Incubate the mixed solution in S1 at 25° C. for 10 minutes, then centrifuge for 10 minutes, and take the supernatant, which is the composition of Example 1.

Embodiment 2

[0032] Embodiment 2: A kind of composition and its preparation method for targeted release of growth factors from platelets

[0033] The composition of growth factor directionally released by platelets comprises: 1 μ l PAR1, 100 ml PRP (autologous platelet-rich plasma, wherein the platelet content is 1×10 7 ), 1 μl heparin.

[0034] Its preparation method is as follows:

[0035] S1. Add PAR1 and heparin to autologous platelet-rich plasma, and manually stir and mix to obtain a mixed solution;

[0036] S2. Incubate the mixed solution in S1 at 25° C. for 10 minutes, then centrifuge for 10 minutes, and take the supernatant, which is the composition of Example 2.

Embodiment 3

[0037] Embodiment 3: A kind of composition and its preparation method for targeted release of growth factors from platelets

[0038] The difference from Example 2 is that PAR1 in Example 2 is replaced by PAR4.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a platelet directional-release growth factor composition and a preparation method thereof, belongs to the field of disease treatment, and aims to provide a method for promotingplatelet directional release of different growth factors so as to achieve the purpose of efficiently treating different diseases. The technical scheme are as follows: the platelet directional-releasegrowth factor composition comprises a PAR thrombin receptor, autologous platelet-rich plasma and heparin; the preparation method comprises the following operation steps: S1, adding PAR and heparin into autologous platelet-rich plasma, and manually stirring and mixing to obtain a mixed solution; S2, incubating the mixed solution in S1, centrifuging, and taking the supernatant to obtain the composition. The platelet directional-release growth factor composition is suitable for enabling the platelets to directionally release the targeted growth factors according to different treatment requirements and eliminating the interference of other growth factors, thereby greatly improving the treatment efficiency of the platelet-rich plasma for different diseases and obtaining a better treatment effect.

Description

technical field [0001] The invention relates to the field of cartilage tissue repair, in particular to a composition for directionally releasing growth factors from platelets and a preparation method thereof. Background technique [0002] Autologous platelet-rich plasma (PRP) is a high-concentration platelet-rich plasma obtained by centrifuging animal or human whole blood. After adding thrombin, it can become a jelly. PRP contains a large number of growth factors such as Platelet-derived growth factor (PDGF), transforming growth factor β (TGF-β), insulin-like growth factor 1 (IGF-1), etc., have been widely used in the wound repair of various tissues, and they have also been widely used in In the clinical treatment of meniscus injury, certain curative effect has been obtained. However, due to the inconsistent results of clinical trials, the efficacy of PRP therapy is still controversial; in short, the growth factors in PRP are mainly released from activated platelets, but pl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K35/16A61K38/17A61K47/36A61P19/08A61P31/04A61P35/00A61P9/10A61K31/201A61K31/727
CPCA61K31/201A61K31/727A61K35/16A61K38/177A61K47/36A61P9/10A61P19/08A61P31/04A61P35/00A61K2300/00
Inventor 黄河徐鸿尧戴志宏邹相杰夏鹏程
Owner NANJING FIRST HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap